Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios
Asset Utilization RatioAssets AverageEBIT MarginEBITDA MarginEBT MarginEnterprise ValueEquity AverageEquity RatioFCF MarginGross MarginInterest Coverage RatioInvested CapitalMarket CapitalizationNet MarginOperating MarginReturn on AssetsReturn on Capital EmployedReturn on EquityReturn on Invested CapitalReturn on SalesTimes Interest Earned

Bicycle Therapeutics (BCYC) EBITDA Margin: 2018-2025

Historic EBITDA Margin for Bicycle Therapeutics (BCYC) over the last 8 years, with Sep 2025 value amounting to -504.58%.

  • Bicycle Therapeutics' EBITDA Margin rose 147206.00% to -504.58% in Q3 2025 from the same period last year, while for Sep 2025 it was 4,374.93%, marking a year-over-year increase of 720398.00%. This contributed to the annual value of -13,967.33% for FY2024, which is 1052667.00% down from last year.
  • Bicycle Therapeutics' EBITDA Margin amounted to -504.58% in Q3 2025, which was up 81.78% from -2,768.97% recorded in Q2 2025.
  • In the past 5 years, Bicycle Therapeutics' EBITDA Margin registered a high of 326.02% during Q4 2023, and its lowest value of -2,768.97% during Q2 2025.
  • Moreover, its 3-year median value for EBITDA Margin was -504.58% (2025), whereas its average is -737.87%.
  • In the last 5 years, Bicycle Therapeutics' EBITDA Margin skyrocketed by 192,044bps in 2022 and then tumbled by 234,032bps in 2025.
  • Bicycle Therapeutics' EBITDA Margin (Quarterly) stood at -2,279.00% in 2021, then surged by 192,044bps to -358.56% in 2022, then skyrocketed by 68,458bps to 326.02% in 2023, then slumped by 16,614bps to 159.88% in 2024, then surged by 147,206bps to -504.58% in 2025.
  • Its last three reported values are -504.58% in Q3 2025, -2,768.97% for Q2 2025, and -624.78% during Q1 2025.